"We are delighted with the continued growth of the brands in China, particularly the increasingly international mix of visitors," commented Haf Cennydd, Brand Director for ICSE, P-MEC, LABWorld and BioPh. "We continuously look to evolve the brands so that our visitors and exhibitors have ample opportunities to maximize their return on investment in attending. Features such as the newly introduced conference series are constantly being developed as a complimentary resource to our guests."
The inaugural China conference series, titled "Pharma R&D and Collaboration Strategies", addressed global pharmaceutical issues, with an emphasis on China's pharma market, across key areas such as New Drug Discovery, Biopharm, Biosimilars, CRO/CMO, API Sourcing, Generics and Export Strategies and more. Thirty eminent speakers from international pharmaceutical companies and research institutes, such as the FDA, Novartis, USP-China, Roche R&D Center, GSK China/HK, AstraZeneca Innovation Centre China, Sanofi-Aventis, Reva Pharma, Dr. Reddy's and Shanghai Pharma, shared their knowledge and research strategies.
For more information about CPhI China (26-28 June, 2012, SNIEC, Shanghai, China), please visit: www.cphi-china.com.
The UBM Live annual schedule of pharma events also includes, Japan (13-15, July, Intex Osaka Exhibition Centre, Japan), South America (25-26, August, Transamerica Expo Centre, Sao Paulo, Brazil 2011), Worldwide (25-27, October, Messe Frankfurt, Germany 2011), and India (30 November – 2 December, 2011, Bombay Exhibition Centre, Mumbai, India).
(1) ARC China December 4, 2010 Newsletter
Notes for Editors:
UBM Live is a division of UBM Plc (LSE: UBM) a leading provider of business information servic
|SOURCE UBM Live|
Copyright©2010 PR Newswire.
All rights reserved